v3.26.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning balance (in shares) at Dec. 31, 2024     8,410,000          
Beginning balance at Dec. 31, 2024 $ 29,317 $ 29,571 $ 8 $ 578,418 $ (81) $ (548,066) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (9,383) (9,383)       (9,383)    
Share-based compensation (in shares)     129,000          
Share-based compensation 516 516   516        
Net proceeds from issuances of common stock (in shares)     84,000          
Net proceeds from issuances of common stock 286 286 $ 1 285        
Proceeds from option exercises (in shares)     4,000          
Proceeds from option exercises 8 8   8        
Unrealized gain on marketable securities 3 3     3      
Foreign currency translation adjustment 28 28     28      
Ending balance (in shares) at Jun. 30, 2025     8,627,000          
Ending balance at Jun. 30, 2025 20,775 21,029 $ 9 579,227 (50) (557,449) (708) (254)
Beginning balance (in shares) at Mar. 31, 2025     8,621,000          
Beginning balance at Mar. 31, 2025 25,102 25,356 $ 9 578,923 (78) (552,790) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,659) (4,659)       (4,659)    
Share-based compensation (in shares)     (22,000)          
Share-based compensation 230 230   230        
Net proceeds from issuances of common stock (in shares)     28,000          
Net proceeds from issuances of common stock 74 74   74        
Unrealized gain on marketable securities 4 4     4      
Foreign currency translation adjustment 24 24     24      
Ending balance (in shares) at Jun. 30, 2025     8,627,000          
Ending balance at Jun. 30, 2025 $ 20,775 21,029 $ 9 579,227 (50) (557,449) (708) (254)
Beginning balance (in shares) at Dec. 31, 2025 8,833,875   8,835,000          
Beginning balance at Dec. 31, 2025 $ 14,601 14,855 $ 9 580,243 (37) (564,652) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (7,418) (7,418)       (7,418)    
Share-based compensation (in shares)     114,000          
Share-based compensation $ 418 418   418        
Net proceeds from issuances of common stock       29        
Proceeds from option exercises (in shares) 79,295   79,000          
Proceeds from option exercises $ 124 124   124        
Proceeds from warrant exercise (in shares)     75,000          
Proceeds from warrant exercise 216 216   216        
Foreign currency translation adjustment $ 20 20     20      
Ending balance (in shares) at Jun. 30, 2026 9,119,004   9,120,000          
Ending balance at Jun. 30, 2026 $ 7,990 8,244 $ 9 581,030 (17) (572,070) (708) (254)
Beginning balance (in shares) at Mar. 31, 2026     9,108,000          
Beginning balance at Mar. 31, 2026 10,672 10,926 $ 9 580,787 (21) (569,141) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (2,929) (2,929)       (2,929)    
Share-based compensation (in shares)     (5,000)          
Share-based compensation 214 214   214        
Net proceeds from issuances of common stock (in shares)     17,000          
Net proceeds from issuances of common stock 29 29   29        
Foreign currency translation adjustment $ 4 4     4      
Ending balance (in shares) at Jun. 30, 2026 9,119,004   9,120,000          
Ending balance at Jun. 30, 2026 $ 7,990 $ 8,244 $ 9 $ 581,030 $ (17) $ (572,070) $ (708) $ (254)